Core Scientific, Inc.
CORZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.06 | 0.00 | -0.00 |
| FCF Yield | -1.45% | 3.75% | -15.26% | -16.27% |
| EV / EBITDA | -3.42 | -33.62 | -0.63 | 9.94 |
| Quality | ||||
| ROIC | -1.29% | 2.44% | -318.11% | 5.62% |
| Gross Margin | 23.71% | 24.57% | 1.31% | 43.87% |
| Cash Conversion Ratio | -0.03 | -0.26 | -0.10 | -1.20 |
| Growth | ||||
| Revenue 3-Year CAGR | -7.26% | -2.65% | 119.77% | 109.14% |
| Free Cash Flow Growth | -206.36% | 127.38% | -54.12% | -357.94% |
| Safety | ||||
| Net Debt / EBITDA | -0.31 | -12.91 | 0.01 | 4.88 |
| Interest Coverage | -0.52 | 0.10 | -21.79 | 3.76 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -17.32 | -143.86 | -30.84 | -12.75 |